Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria-tetanus-acellular pertussis vaccine
- Development stage
- Approved
- Lead developer
- Clifford Craig Medical Trust Fund
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The diphtheria-tetanus-acellular pertussis (DTaP) vaccine is a combination biological product designed to provide active immunity against *Corynebacterium diphtheriae*, *Clostridium tetani*, and *Bordetella pertussis*. It contains toxoids (inactivated toxins) from diphtheria and tetanus, along with acellular components of the pertussis bacterium, such as pertussis toxoid, filamentous hemagglutinin, and pertactin. In the context of research conducted by the Clifford Craig Medical Research Trust (NCT02765126), this vaccine is being evaluated for its heterologous or non-specific immunological effects. Specifically, the study investigates how DTaP vaccination influences generalized inflammation, immune homeostasis, and the subsequent immune response to seasonal influenza vaccination in elderly individuals and healthy adults.
- Other names
- diphtheria-tetanus-acellular pertussis vaccine-Clifford Craig Medical Research Trust-diphtheria-tetanus-pertussisDTaP vaccineDTP vaccine
02
Targets
FHA (Filamentous hemagglutinin)PRN (Pertactin)FIM2/FIM3 (Fimbriae types 2 and 3)TT (Tetanus toxoid)
Beyond the preview
Go deeper on diphtheria-tetanus-acellular pertussis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria-tetanus-acellular pertussis vaccine.